PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography

Fech, Viktor; Alberts, Ian; Rominger, Axel; Afshar-Oromieh, Ali (2019). PSMA-ligand PET allows a more accurate therapeutic response evaluation of bone metastases in prostate cancer compared to computed tomography (In Press). Nuklearmedizin Thieme 10.1055/a-0895-5078

[img] Text
Fech_Case Report.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (994kB) | Request a copy

A patient with bone metastases of prostate cancer was referred for 68Ga-PSMA-11 PET/CT. Compared to a 68Ga-PSMA-11 PET/CT four months previously, the CT-component of the current PET/CT showed morphological progress in all lesions despite continuous therapy with docetaxel and denosumab. Contrarily, the PET-component showed a reduction of tracer-uptake, which correlated with PSA decrease between the two PET/CT-scans (16.2 ng/ml vs. 3.1 ng/ml). This case highlights 68Ga-PSMA-11 PET/CT as a promising tool for therapy monitoring of prostate cancer and could serve as a basis for a novel monitoring strategy. Volume progress shown by CT must not be classified as tumor progress, but as bone remodeling following effective therapy.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Fech, Viktor; Alberts, Ian Leigh; Rominger, Axel Oliver and Afshar Oromieh, Ali

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0029-5566

Publisher:

Thieme

Language:

Multilingual

Submitter:

Sabine Lanz

Date Deposited:

18 Dec 2019 10:14

Last Modified:

19 Dec 2019 01:31

Publisher DOI:

10.1055/a-0895-5078

PubMed ID:

31083752

BORIS DOI:

10.7892/boris.132408

URI:

https://boris.unibe.ch/id/eprint/132408

Actions (login required)

Edit item Edit item
Provide Feedback